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POLISI PENETAPAN HARGA UBAT: IMPAK PADA TAHAP SEDIA ADA 
DAN KEMAMPUAN MEMBELI UBAT DI EMPAT NEGERI DI INDONESIA 
 
ABSTRAK 
Kerajaan Indonesia telah memberikan komitmen untuk penyediaan ubat-ubatan 
dengan harga yang berpatutan. Kerajaan membangun polisi harga runcit maksimum 
bagi ubat generik dengan nama International Non-proprietary Name (INN). Objektif 
kajian ini adalah untuk menilai impak polisi harga ubat terhadap harga, tahap sedia 
ada, kemampuan membeli ubat, dan menilai kandungan dan konteks dalam 
pembangunan polisi harga ubat di Indonesia. Bahagian pertama kajian dilaksanakan 
dengan menggunakan metodologi yang dibangunkan oleh Pertubuhan Kesihatan 
Sedunia (WHO& HAI). Harga, tahap sedia dan kemampuan membeli ubat diperoleh 
dari  sektor awam,  swasta, dan sektor yang lain di 4 negeri di Indonesia (Sumatera 
Selatan, Jakarta, Yogyakarta dan Sulawesi Selatan). Jenis ubat yang dipilih adalah 
ubat generik dengan  harga paling rendah (LPGs) dan ubat berjenama (IB). Harga 
rujukan antarabangsa tahun 2009 (IRP) telah digunakan untuk mengira nisbah harga 
median (MPR). Bahagian kedua kajian telah dijalankan untuk memperolehi 
maklumat dan konteks dalam pembangunan polisi harga ubat. Kaedah yang 
digunakan ialah: penilaian dokumen mengenai dasar-dasar penentuan harga ubat, 
temu bual mendalam dengan 10 pemberi maklumat utama dan 10 pemerhatian 
kepada mesyuarat rasmi mengenai harga perubatan. Transkrip dianalisis 
menggunakan analisis kandungan kualitatif. Kaedah triangulasi digunakan untuk 
membandingkan data yang diperolehi daripada penilaian dokumen, temu bual secara 
mendalam dan pemerhatian mesyuarat.  Harga beli ubat di sektor awam masih tidak 
cekap, kerana MPR lebih tinggi berbanding IRP (1.34). Harga beli ubat sektor awam 
xx 
 
cekap apabila MPRs  ≤ 1. Di semua sektor, harga ubat berjenama adalah  mahal, 
MPRs 7-133 dibandingkan IRP. Ubat berjenama lebih sering ditemui di sektor 
swasta dan lain daripada di sektor awam. Perbezaan harga ubat di antara sektor dan 
negeri adalah tidak signifikan secara statistik. Selepas penetapan polisi, harga ubat 
LPGs didapati lebih rendah di dibandingkan sebelum penetapan polisi. Ubat LPGs 
dijual melebihi harga yang ditetapkan oleh kerajaan. Tahap sedia ada di sektor awam 
serupa dengan sebelum pelaksanaan polisi harga ubat, sementara di sektor swasta 
tahap sedia ada menurun. Pekerja di sektor awam dengan pendapatan paling rendah 
lebih mampu membeli ubat generik dibanding ubat berjenama. Kerajaan mengawal 
selia harga ubat generik tidak berjenama dengan menggunakan kaedah cost-plus 
pricing. Proses pembangunan polisi harga ubat generik telah berpatutan, namun 
penggunaan hasil kajian mengenai harga ubat, pautan antara institusi kerajaan dan 
organisasi antarabangsa, dan penggunaan hasil pemantauan belum dioptimumkan. 
Pilihan polisi harga ubat di Indonesia yang didedahkan oleh kajian ini ialah: 
membangunkan senarai positif,  persaingan harga, perundingan, perbandingan harga 
dan pengurangan cukai. Strategi yang dicadangkan menggabungkan dengan sistem 
insurans. Sebagai kesimpulan, polisi harga ubat generik telah berjaya dalam 
mengurangkan harga LPGs. Tidak ada polisi harga ubat yang dibangun kerajaan 
untuk mengawal harga ubat berjenama dan berjenama generik. Polisi harga ubat 
generik tidak menjejaskan tahap sedia ada di sektor awam, tetapi ia mengurangkan 
tahap sedia ada di sektor swasta. Terdapat keperluan untuk melakukan 
penambahbaikan terhadap proses pembangunan polisi harga ubat. 
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MEDICINE PRICING POLICIES:  THE IMPACT ON AVAILABILITY AND 
AFFORDABILITY IN FOUR PROVINCES IN INDONESIA 
 
ABSTRACT 
The government of Indonesia has established a commitment to the provision of 
affordable medicines. The retail price of unbranded generic cannot exceed the 
maximum retail price set by the Ministry of Health. The generic medicine pricing 
policy that has been implemented by the Indonesian government must be evaluated. 
The objectives of this study were to evaluate the impact on the price, availability and 
affordability of selected medicines and to evaluate the context, process, evidence and 
links of generic medicine pricing policies development in Indonesia. The first part of 
the study was conducted using a standardized methodology developed by the World 
Health Organization and Health Action International. The prices, availability and 
affordability of 50 medicines were measured at public, private and NGO facilities in 
four provinces in Indonesia (Sumatera Selatan, Jakarta, Yogyakarta and Sulawesi 
Selatan). The type of medicines selected were Lowest Price Generics (LPGs) and 
Innovator Brands (IBs). The 2009 International Reference Price (IRP) was used to 
calculate the median price ratio (MPR). The second part of the study was conducted 
using the following methods: a review of medicine pricing policies documents, in-
depth interviews with 10 key informants and 10 observations of meetings about 
medicine prices. Transcripts were generated and analyzed using qualitative content 
analysis. Triangulation was applied to the comparative information obtained from 
document reviews, in-depth interviews, and meeting observations. The results 
showed that the public sector procurement price was still inefficient (MPRs=1.36). 
Public sector procurement price is efficient if the MPR ≤ 1. The prices of IBs were 
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found to be very expensive, the MPRs around 7-133 times than IRP. The IBs were 
found more often in private and NGO hospitals than in the public sector. A small 
variation in LPGs prices and availability were found among sectors and provinces. 
The prices of LPGs medicine lowered after the implementation of the medicine 
pricing policy. However, the LPGs was sold above the maximum price of MoH. The 
availability of LPGs in the public sector had been similar in terms of availability 
before the medicine pricing policies were implemented, while in the private sector it 
had decreased. The LPGs are generally more affordable for the lowest paid 
government workers than for the IBs. The Indonesian government regulated the price 
of unbranded generic medicines by using a cost-plus pricing method. The 
development process of medicine pricing policy was well established. However, 
links among government institutions in the monitoring activities has not been 
optimized. The use of evidence was limited. The medicine pricing policy options 
revealed in this study include the development of a national positive list, price 
competition, negotiation, price comparisons and tax reduction. The proposed 
strategies have been incorporated within the insurance system. In conclusion, generic 
medicine pricing policies have succeeded in lowering the price of LPGs in all 
sectors, but many outlets still sell LPGs at a price which is above the maximum 
price. The generic medicine pricing policy does not affect availability in the public 
sector, but it decreases availability in the private sector. There is a lack of a policy to 
regulate the high price of branded generic medicine and IBs. Therefore, there is a 
considerable need to improve medicine pricing policy in Indonesia.  
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CHAPTER ONE 
GENERAL INTRODUCTION 
 
1.1 BACKGROUND 
Medicine plays an important role in the health care system. In developing countries, 
medicines account for approximately 20–60% of health expenditures (WHO, 2004a). 
Medicine is one of the factors that cause inefficiency in the health care service. 
Owing to the rising cost of health care in developing countries, it is crucial to keep 
health care services available and affordable by the community (WHO, 2010a). Most 
people in developing countries use out-of-pocket payments to purchase medicines, 
making them unaffordable and inaccessible. 
 
Public access to medicines should be a concern for both governments and private 
health providers. The accessibility of medicine can be affected by price and 
availability. People cannot access medicine due to low availability and high price 
(Donald et al., 2011). Governments should play a major role in developing medicine 
policies to ensure their availability and affordability (WHO, 2004b). 
 
Industry pricing policies, government pricing policies, national health policies, 
excessive patent extensions or the monopoly of the production of certain medicines 
all affect the price of medicines (Olcay and Laing, 2005). To reduce the price of 
medicines, regulation can be implemented at different stages of the supply chain such 
as wholesale prices, retail prices, drug taxes and reimbursement prices (Aaserud et 
al., 2006). In many countries, regulations regarding medicine pricing policy have 
been implemented. 
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In addition to price, availability is another important factor towards ensuring access 
to medicines. Low availability in the public sector has often occurred in low income 
and Low/Middle Income Countries (LMIC). For example, very low availability has 
been observed in Yemen. Moreover, regional availability is also low in Africa 
(29.4%) compared with 54.4% in the US (Cameron et al., 2009). Mean availability in 
the public sector is lower than that in the private sector in all regions in the world 
(Cameron et al., 2011). 
 
In the public sector, the low availability of medicines can affect affordability. Some 
public sectors provide free or low priced medicines. However, when medicines are 
unavailable in the public sector, patients are forced to buy them in the private sector 
where medicine prices may be more expensive (Cameron et al., 2011). Economies 
are divided according to 2012 GNI per capita,. The groups are: low income, $1,035 
or less; lower middle income, $1,036 - $4,085; upper middle income, $4,086 - 
$12,615; and high income,$12,616 or more (World Bank, 2012). According to this 
classification, Indonesia is classified as a lower middle-income country and 
developing countries (United Nations, 2012). Therefore Indonesia is also facing 
similar problems on the medicines. To describe the medicine price problems in 
Indonesia, it is important to understand the Indonesian health care system and its 
pharmaceutical system. 
 
1.1.1 Indonesian Health Care System 
Decentralisation in the health care system has been implemented since 2001. Under 
this system, districts and municipalities have more authority and responsibility for 
government services and financial planning. Budget control and health planning have 
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also moved from the central level directly to the district or municipality (WHO, 
2010b).  
 
The central government has the responsibility of maintaining health care services in 
terms of developing and setting national standards, national indicators, national goals 
and national training modules for health care professionals, advocating for continued 
health financing and increasing the access of the poor to public health services 
(Holloway, 2011). The organizational structure of Indonesian health care system in 
the decentralization is shown in Figure 1.1. 
 
 
Figure 1.1 Organizational structure of Indonesian health care system. Adapted from 
Country Health System Profile, WHO, 2010. 
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1.1.1.(a) Indonesian health insurance  
The government of Indonesia is establishing universal health coverage (UHC) for all 
Indonesian citizens under Law number 40/2004. The law has been issued but the 
implementation of it will be carried out in 2014. To date, the coverage of government 
social insurance (ASKES, JAMKESMAS and JAMKESDA) is about 40% and 2% 
by private insurance (Holloway, 2011). ASKES is a health insurance that covers civil 
servants and their families. Private employers and workers are covered by 
JAMSOSTEK.  Both ASKES and JAMSOSTEK deduct the salary of the employee 
to pay the premium. JAMKESMAS is health insurance for the poor, with the 
premium paid by the government. 
 
By 2014, it is expected that all Indonesian citizens will be covered by health 
insurance under the Indonesian UHC. The government is developing a system for 
UHC implementation, including a pharmaceutical system. ASKES was appointed as 
the implementing agency of the Social Security Providers (namely Badan 
Penyelenggara Jaminan Sosial) for the health sector, which was mandated by the 
2004 National Social Security System (SJSN) Law. 
 
1.1.1.(b) Mortality and morbidity in Indonesia 
The blood circulation system is the main cause of morbidity and acute respiratory 
infection for mortality. Table 1.1 shows the top 10 diseases that cause mortality and 
mortality in Indonesia (MoH, 2010a). 
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Table 1.1 Top 10 diseases that cause mortality and morbidity 
Disease Mortality Morbidity 
Disease 1 Blood circulation system Acute upper respiratory tract infection 
Disease 2 Infections and parasitic disease Unspecified fever 
Disease 3 Specific conditions initiated in perinatal states Skin and subcutaneous diseases 
Disease 4 Respiratory disease Diarrhoea and gastroenteritis 
Disease 5 Gastrointestinal disease Refraction and accommodation  (eye disorder) 
Disease 6 Trauma, poisoning and other external causes Dyspepsia 
Disease 7 Endocrine, nutritional and metabolic disease Primary essential hypertension 
Disease 8 Urinary tract system Pulp and periapical disease 
Disease 9 Neoplasm Ear and mastoid processus disease 
Disease 10 Other (unspecific signs, symptoms or laboratory results 
Conjunctivitis and other 
conjunctival disorder 
 
1.1.2 Indonesian Pharmaceutical System 
The pharmaceutical system in Indonesia plays a role in the public and private sectors. 
The Ministry of Health is responsible for ensuring the medicine supply in the public 
sector. Since decentralisation in 2000, drug supply in the public sector has been 
managed by local district governments. The district health office procures the 
medicines from distributors by tender. Medicines are then distributed to all primary 
health care facilities, such as primary health care centres (PUSKESMAS), sub-
primary care centres (PUSTUS), maternal child health clinics (POLINDES), 
community clinics (POSYANDUS) and mobile clinics (PUSKESLING) (Holloway, 
2011). Patients receive medicines from these facilities free of charge. 
 
Besides district health offices, district public hospitals also play an important role in 
the supply of public medicines. A difference mechanism is used by public hospitals 
to procure their medicines. Public hospitals procure medicines directly from 
wholesalers or distributors. In public hospitals, patients still have to pay for their 
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medicines if they are not covered by insurance. For the patient who is covered by the 
JAMKESMAS, ASKES and JAMSOSTEK insurance, public hospital services only 
for the secondary care.  The patients have to go to primary health center or family 
general practioner for the primary care. The supply chain structure in the public 
sector is shown in Figure 1.2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Structure of the public sector pharmaceutical supply in Indonesia 
 
In the private sector, the medicine supply chain begins in the pharmaceutical 
industry. In 2011, there were 202 pharmaceutical industries (Indonesian Drug 
Regulatory Agency, 2011). Four industries are state-owned enterprises and eight are 
domestic industries that produce generic medicines. Domestic industries dominate 
the market for branded generic medicines.  
 
Originator brands and new medicines are produced by multinational industries. 
Pharmaceutical industries should produce their medicines in Indonesia, under Decree 
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1010, only companies registered as ‘licensing pharmaceutical companies’ will be 
allowed to obtain marketing approval (MoH, 2008a). Imported medicines are 
allowed only for special cases and programs and need the approval of the MoH and 
Drug Regulatory Agency.   
 
Pharmaceutical industries sell their medicines to distributors. About 2600 distributors 
sell these medicines to pharmacies, hospitals and licensed drug stores. Patients can 
receive medicines from pharmacies, hospitals or licensed drug stores through out-of-
pocket expenses or by being covered by private insurance. The supply chain in the 
private sector is shown in Figure 1.3 (Wang et al., 2009). 
 
 
Figure 1.3 Structure of the private sector pharmaceutical supply in Indonesia. 
Adapted from: Private Sector Health in Indonesia: A Desk Review by 
Wang et al, 2009, Bethesda, MD: Health Systems  
 
Data in Indonesia show that GDP per capita in 2010 was US$ 2980.843 (IMF, 2010). 
Per capita spending on medicines is slightly over US$ 12 annually. Compared with 
GDP per capita, spending on medicines in Indonesia is low (Wang et al., 2009). The 
pharmaceutical market in Indonesia in 2010 was valued at around US$ 3.787 billion. 
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The public sector market (health centres and public health programs) has a share of 
around 10–12%, while the public hospital market share is around 12-15% (World 
Bank, 2008). The data described for the public sector market share are lower than 
that in the private sector.  
 
In Indonesia, most people purchase medicines through out-of-pocket payments, 
around 60% to 85%.  (Wang et al., 2009). In choosing a medicine, Indonesian 
consumers are influenced by brand name medicines, although cheaper generic 
medicines are available (World Bank, 2008). In fact, survey results in LMIC and low 
income countries show the percentage difference in price between originator brands 
and low priced generics (LPGs) in the private sector to be above 300% (Cameron et 
al., 2009). This situation, in turn, can lead patients to pay higher prices for the same 
medicines and same degree of effectiveness.  
 
Besides the mark-ups on the price of medicines, high prices could also be caused by 
taxes and mark-ups (WHO and HAI, 2008). In Indonesia, value added tax (VAT) is 
applied to medicines. Taxes on medicines should be a part of government concern in 
the development of medicine pricing policy. 
 
The government of Indonesia has given a political commitment to improve society's 
ability to access medicines by implementing the National Drug Policy. This is 
broadly aimed at assuring the sustainable and fair distribution and affordability of 
medicines to achieve the highest standards of public health. The component of the 
Indonesian National Drug Policy are: financing, availability and acces, equitable 
distribution, affordability, the selection of national essential medicines, rational 
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medicine use, quality assurance on safety and efficacy of the medicine, research and 
development, human resources development and monitoring and evaluation (MoH, 
2006a). 
 
This commitment is also shown through the development and implementation of 
several medicine pricing policies. The government sets a maximum retail margin for 
unbranded generic medicines. However, most policies issued by the government only 
regulate the price of generic medicines with an International Non-proprietary Name 
(INN). In addition, the Indonesian pharmaceutical market is dominated by branded 
generics (generic medicines with company brands). The market share of unbranded 
generic medicines ranges from 10% to 15% of the total medicines market in 
Indonesia. Originator, patent and branded generic medicine prices are not regulated 
by the government.  
 
The pricing mechanism of branded generic and originator brand medicines are 
mainly left to market forces (see Figure 1.4). Therefore, the price of innovator or 
branded generic medicines in Indonesia could be three to 100 times more expensive 
than generic medicines (Siahaan et al., 2004). Based on this condition, there is a need 
for an appropriate medicine pricing policy or pricing mechanism that can cover the 
public and private sectors in Indonesia. 
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Figure 1.4 Schematic diagram medicine pricing policy mechanisms in Indonesia 
 
1.2 PROBLEM STATEMENT 
The price of medicines is one of the obstacles to accessing medicines in Indonesia. 
Several studies in Indonesia show the price of medicines to be high (Siahaan et al., 
2004; Siahaan, 2006; Restuani and Anggriani, 2009). 
 
The availability of medicines in Indonesia is often low, especially for unbranded 
generic medicines (Siahaan et al., 2004). Generic medicines with brand names and 
off-patent medicines (originator medicines) can often be better known than 
unbranded generic medicines. Furthermore, the prices of brand name and originator 
medicines are higher than unbranded generic medicines. Thus, the affordability of 
medicines is a problem in the Indonesian health care system. People in Indonesia 
often pay for expensive medicines. In fact, the per capita income of Indonesia's 
population is still in the group of Middle Income Countries, with a per capita GDP of 
U$ 2980.43 in 2010 (IMF, 2010). In addition, recent data from the Indonesia's 
Central Statistics Agency stated that 12.36% of the population are classified as poor 
condition. Indonesian government's official poverty line of 233,740 rupiah per capita 
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Unbranded generic 
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per month, which is less than $28 dollars (BPS, 2012). If unbranded generic 
medicine availability is low, people have to buy medicines at more expensive prices; 
as a result, the poor would find it difficult to buy the medicine, and even for middle-
income residents, providing expensive medicine for long-term treatment, such as for 
chronic diseases, may lead to poverty (Niens et al., 2010).  
 
The high price of medicine and low availability are also an issue for healthcare 
services. Healthcare services that are mainly owned by the government have limited 
funds to run the health service. If medicines are not available at low prices, then 
healthcare facilities should provide more funds for the branded generic medicine or 
originator medicine. This situation results in inefficiencies in the medicine 
management by healthcare facilities, such as low availability of medications or the 
availability of only branded generic and innovator medicine at a more expensive 
price. Low availability of medicines will affect the quality of health care because the 
patients cannot gain access to medicines at affordable prices. In the end, this will 
cause problems of morbidity and mortality. 
 
Another problem in Indonesia, is that there is no evidence on developing medicine 
pricing policies. The content, context, actors and criteria used in determining the 
price of medicines in the policy remain unclear. 
 
1.3 RATIONALE AND IMPORTANCE OF THE STUDY 
Between 2005 and 2011, the government of Indonesia implemented a number of 
pricing policies in order to set the maximum retail price (MRP) for generic medicines 
and a procurement price for the public sector. However, rapid changes in medicine 
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pricing policies often occur in Indonesia. For example, in 2006 the prices in the 
policy were changed twice. Such frequent changes in price can cause problems 
during implementation and may result in an ineffective policy. The previous policy 
was still in the socialisation program or just at the beginning of the implementation 
stage when another new policy was released. Thus, the impacts of the previous 
policy are unknown. 
 
Rapid changes can indicate suboptimal policy development. However, the 
availability of scientific evidence is insufficient to help determine whether medicine 
prices, availability and affordability have improved after the implementation of these 
policies. No systematic evaluation has been conducted to assess the effectiveness and 
impact of these pricing policies. 
 
An appropriate medicine pricing policy should be developed around the following 
main principles: scientific evidence-based, a fair and transparent process and 
linkages between the key actors involved in policy development. Moreover, the 
policy and institutional context are also important factors that should be considered  
(Start and Hovland, 2004). Furthermore, the development of the medicine pricing 
policy is an important part of establishing good policy. For example, it is important 
to involve various parties or stakeholders in the development process (Gilson, 2012). 
However, little attention has been paid in evaluating whether the policy development 
process was carried out in accordance with the stages established in the policy 
guidelines. 
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The key actors can be identified at national or international levels. At the national 
level, the key actors can be categorised as (i) persons responsible for policy 
development including internal government and outside government institutions; (ii) 
persons responsible for implementing the policy, such as middle managers, health 
workers, patients and citizens; (iii) and civil society or interest groups who seek to 
influence the formal policy process (Gilson, 2012). The role of key actors in 
developing the medicine pricing policy in Indonesia has not been explored. 
 
Based on the above description, the price of medicines in Indonesia remains an 
important issue for the government, pharmaceutical industry, third party (insurance) 
providers as well as consumers. Therefore, there is a need to investigate the price of 
medicines as well as their availability and affordability after medicine pricing 
policies have been implemented. Moreover, a good policy is necessary to achieve the 
goal of increasing availability and at affordable price. It is also important to evaluate 
the mechanism used in developing medicine pricing policies. 
 
1.4 OBJECTIVES 
1.4.1 General Aim 
The main aim of the research is to evaluate the impact of government policy 
intervention on the price, availability and affordability of selected important 
medicines in order to improve access to affordable medicines for all.  
1.4.2 Specific Aims 
In order to achieve the general aim, the study has the following specific aims:  
(i) To compare public sector procurement prices with the prices paid by patients in 
the public and private sectors.  
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(ii) To compare retail prices of 50 medicines across different segments of health 
care sectors and provinces.  
(iii) To compare availability of 50 medicines across different segments of health 
care sectors and provinces.  
(iv) To evaluate the affordability of the treatment costs of selected diseases (i.e. 
Hypertension, Diabetic, Asthma). 
(v) To evaluate the impact of government policy intervention on medicine prices 
and availability. 
(vi) To identify strengths, weaknesses, contexts, content and evidence in developing 
medicine pricing policies. 
(vii)  To identify policy options for improving medicine pricing policy development 
and implementation in Indonesia. 
 
1.5 CONTRIBUTION OF THE STUDY 
The findings of this study describe medicine prices, availability and affordability 
after the government of Indonesia implemented a series of medicine pricing policies. 
The findings also provide data on the effectiveness, pricing trends, impacts and 
mechanism used in developing the implemented policies.  
 
The findings of this study could contribute to the government to develop effective 
medicine pricing policies and the implementation strategies in Indonesia. Moreover, 
the government can adopt the survey method used in this study to monitor and 
evaluate the implementation of the medicine pricing policy regularly.  
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Information from this research could also be used by health care facilities both in 
public and private sectors as a basis for negotiating more affordable prices for 
medicines.    
The results of this study may be used as information for the pharmaceutical industry 
about the situation concerning the price and availability of medicines in Indonesia. 
Furthermore, the pharmaceutical industry could use the information from this study 
to prepare their pricing strategies.  
 
The pharmacy profession could further enhance its role in health care by providing 
information on the alternative choices of similar medicines at different prices. 
Furthermore, this study is expected to provide benefits to patients, their families and 
the general public who could have easier access to the required medicines at 
affordable prices. 
 
Data on availability, price and affordability are required by both local and 
international NGOs, International agencies and health professionals to map, create 
programmes and provide advocacy related to increasing people's access to essential 
medicines at affordable prices.  
 
1.6 SYNOPSIS OF THE THESIS 
This thesis is divided into five chapters. The following Chapter 2 provides a 
literature review and a conceptual framework on medicine pricing policy as well as 
on price, availability and affordability. An overview of policy analysis processes is 
also presented in this chapter. Chapter 3 presents the methodology and results of the 
study regarding the impact of the medicine pricing policy on price, availability and 
16 
 
affordability. The compliance of health facilities to medicine pricing policies is also 
described in this chapter. Chapter 4 describes the results of the qualitative study on 
the evaluation of the Indonesian medicine pricing policy. This chapter also presents 
policy options for Indonesia based on the content and context. The thesis concludes 
in Chapter 5 with a summary of the study. This chapter also proposes a number of 
recommendations to improve the implementation of the medicine pricing policy in 
Indonesia. In addition, the limitations of the study are describes in this final chapter. 
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CHAPTER TWO 
LITERATURE REVIEW AND 
DEVELOPMENT OF CONCEPTUAL FRAMEWORK 
 
2.1 MEDICINE PRICING POLICY 
Medicine is a pharmaceutical product that has imperfect market characteristics. 
Consumers or patients cannot directly determine their treatment options, since 
treatment was determined by the physician. In addition, the patient often does not 
obtain complete information regarding their treatment options and price. Because of 
these characteristics, medicine prices could be more expensive than they should be. 
This affects affordability to the community, and therefore it is necessary for the 
government to regulate medicine prices (WHO, 1998). 
 
Determining a "fair" price could be achieved by regulating medicine prices, but this 
is the most difficult part of the development of a medicine pricing policy. Medicine 
prices can be regulated in the medicine supply chain by the industry, importers, 
distributors and health facilities such as pharmacies, hospitals and medicine sellers. 
In practice, the government may use a combination of regulations in each chain. For 
example, the government sets the price at the pharmaceutical industry level and the 
maximum mark-up that can be taken by wholesalers or health care facilities (WHO, 
1998; Rietveld and Haaijer-Ruskamp, 2002).   
 
2.1.1 Price Regulation in the Production Stage 
Price setting in this stage is conducted in the pharmaceutical industry or at the 
importer level. According to Rietveld and Haaijer-Ruskamp (2002), at this level 
there are five methods for setting medicine prices. 
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2.1.1.(a) Cost-plus 
Pricing is set by calculating the cost of production, cost of raw materials, R&D and 
margin for each product. Policymakers negotiate with the pharmaceutical industry to 
establish the margin for each product. This method complicates obtaining production 
cost information. The pharmaceutical industry is often not transparent and can 
manipulate the information provided (WHO, 1998). India has implemented a cost-
plus pricing method for essential medicines whereby it cannot exceed twice the cost 
of their production (Kumar, 2004). 
 
2.1.1.(b) Profit ceilings/Profit-based pricing 
Here, the government sets a maximum return on capital (ROC) and return on sales 
(ROS) to the pharmaceutical industry that sells their products to the government. The 
system implemented in the UK is termed the Pharmaceutical Price Regulation 
Scheme (PPRS) (Borrell, 1999). ROC or ROS are set individually by the 
pharmaceutical industry and reviewed every year. In 2009, the ROC was set at 21% 
and ROS at 6% (Department of Health UK, 2012). 
 
According to Mossialos (2006), the PPRS is unique in its implementation, as the 
buyer’s power is very large. In this case, there is a unique relationship between the 
government and pharmaceutical industry, since the disclosure of information by the 
pharmaceutical industry might not be applied universally. Similar to the cost-plus 
pricing method, there is also the disadvantage of the manipulation of information by 
the pharmaceutical industry (WHO, 1998). 
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2.1.1.(c) Price comparison 
Pricing is set by comparing medicine prices within a country or with other countries 
(WHO, 1998). Internal/national reference pricing sets the price of one medicine for a 
group of medicines with the same therapeutic classes or that have the same function 
in a single country. Reference prices can be based on the average price or lowest 
price in the group. This method is commonly used to establish the reimbursement 
price of a medicine (Danzon and Chao, 2000; Huttin, 2002; Schneeweiss, 2007).  
The pharmaceutical industry can set the price according to what they want, while the 
government or insurance provider only pays the reference price and the consumer 
must pay the difference (Ghislandi, 2011). The implementation of national reference 
pricing in Norway, Germany, Sweden, South Africa and Canada has reduced the 
price of medicines (Aronsson et al., 2001; Pavenik, 2002; Rothberg et al., 2004; 
Brekke et al., 2009). New Zealand has also implemented internal reference pricing 
(Huttin, 2002; Aaserud et al., 2006). 
 
Price setting by comparing the prices of the same medicine in other countries is 
called international/external reference pricing. In 2010, external reference pricing 
was widely used in 23 countries in Europe, except Denmark, Germany, Sweden and 
the UK. Reference baskets (other countries used for comparison) were used by the 
state in fewer than 10 countries from the same economic level. In general, EU 
countries use the average price of the reference country. Most countries in Europe 
make external reference pricing the primary criteria for price setting, except in 
Belgium and Italy where it is used as supporting information (Dylst and Simoens, 
2010; Leopold et al., 2012).  In 2012, the UK additionally performed an international 
price comparison in setting the ceiling profit of the PPRS (Department of Health UK, 
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2012). Many studies show the reference price to be an effective method of reducing 
the price of generic medicines, but the reference pricing system is ineffective for 
medicines that are still under patent (Mossialos et al., 2006). 
 
2.1.1.(d) Price negotiation 
Pricing is set by negotiating medicine prices between the buyer (e.g., hospitals, 
health insurance or government) and the industry. It is usually implemented on the 
purchase of large volume or value. Therefore, buyers have a great bargaining 
position. Negotiations can be carried out centrally or at a local level (Rietveld and 
Haaijer-Ruskamp, 2002).  This strategy has been used in Austria, France, Spain and 
Sweden (Mrazek, 2002). 
 
2.1.1.(e) Pharmacoeconomic evaluation 
Price setting is carried out by evaluating the cost-effectiveness of a medicine. In 
general, pharmacoeconomic evaluation is used to determine the price of medicines in 
the insurance system that requires more consideration of the value for money. In 
principle, phamacoeconomic evaluation can calculate the value of the benefits gained 
by the new medicine compared with established medicine  (Drummond et al., 1997). 
The value then would be appraised for cost-effectiveness, usually by the use of a 
threshold (public willingness to pay for a gained in health benefit) (McGuire et al., 
2004). The value would increase with lower price or improved benefit. As such, the 
evaluation is commonly used to bargain for lower price in order to justify its value 
for reimbursement. 
 
21 
 
This method is applied in Australia  and the Ontario province in Canada (Bloor et al., 
1996). EU countries such as Finland, the Netherlands (Hoomans et al., 2012), 
Sweden (Lundkvist, 2002) and the UK (National Institute for Health and Clinical 
Excellence/NICE) had conducted economic evaluations to determine the medicines 
that provide “value of money”.  In addition to the UK and Canada, this system has 
also been implemented in France, Germany, Italy, Spain and Switzerland. There is a 
variation in the application of EU economic evaluation; this system is generally used 
for setting medicine prices for reimbursement. Furthermore, Finland, France, 
Norway and Sweden use economic evaluation guidelines for negotiations (Graf von 
der Schulenburg and Hoffmann, 2000). In Asia, South Korea is the first Asian 
Countries which is implemented the  economic evaluation to determine the price for 
reimbursement (Yang et al., 2008). 
 
2.1.2 Regulation of Medicine Prices at the Distribution Level 
Rietveld and Haaijer-Ruskamp (2002) classify price settings at the distribution level: 
 
2.1.2.(a) Setting the price at the wholesaler or distributor level 
Regulation is implemented by limiting the distribution margin distributor or 
wholesaler. In addition to applying the external or internal price comparison system, 
21 of the 27 countries in Europe also regulate wholesaler mark-ups (Vogler et al., 
2008). Other countries that regulate wholesaler mark-ups are Ecuador, Honduras, 
Panama and Paraguay (Sarmiento, 1995). 
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2.1.2.(b) Price setting at the pharmacy level 
Price setting in pharmacies can be carried out from two perspectives: (1) 
medicine/product-oriented and patient/services-oriented. There are three methods for 
setting prices based on the orientation of the product. First, in the Fixed Margin (Cost 
+ fixed percentage) method, the amount of mark-up is fixed, e.g., the maximum 
mark-up that could be taken is 25%. Second, in the Mark-up Negotiation, the mark-
up is set by negotiation between the distributor and buyer (e.g., health insurance, 
government or hospital). Third, the mark-up may be Digressive/Cost + declining 
percentage, where the mark-up is determined based on the proportion of the price. If 
the medicine price were high, then the mark-up allowed would be low, and vice 
versa. 
 
Medicine prices based on services (patient-oriented) are set by co-payment and fixed 
fees per prescription. Co-payment methods are applicable in South Korea and are 
used to reduce medicine expenditure per patient and the per-unit price of medicines 
(Lee et al., 2012). The application of co-payment in Medicare Beneficiaries lowers 
the expenditure of medicines to 14% due to the increased use of generic medicines 
(Gilman and Kautter, 2008). In addition to conducting pharmacoeconomic 
evaluations when pharmaceutical companies propose their medicines, the 
Pharmaceutical Benefits Scheme in Australia also regulates the price of medicines to 
patients using a co-payment system. The patient must pay the difference in price if he 
or she wants a medicine that exceeds the cost of the co-payment (PBS, 2012). 
 
In Ireland, the pharmacist receives a fixed fee per prescription for patient services to 
members of general medical services and drug payment schemes. There are 
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differences in determining the price of the medicine under both schemes. Under 
general medical services, medicine prices are in accordance with the prices set by the 
government and pharmacists cannot apply a profit mark-up. Under drug payment 
schemes, pharmacies can add a 50% mark-up from the medicine prices set by the 
government. For patients not under any schemes, medicine pricing is fully depends 
to the pharmacy (Purcell, 2004). 
 
2.1.3 Impact of the Implementation of Medicine Pricing Policies in the 
Pharmaceutical Industry 
Medicine prices can be reduced by implementing a medicine pricing policy. 
However, such a policy may also provide unintended impacts. Along with a decrease 
in medicine prices, the profit of the pharmaceutical industry will reduce (Sood et al., 
2009), which can decrease a company’s spending on innovation research (Vogel, 
2004; Golec and Vernon, 2006).  
 
The impact of medicine pricing policy is influenced by the size of the regulated 
market and the length of the policy applied. If the medicine pricing policy was 
applied to the previously non-regulated countries, then it would generate a big impact 
of revenue reduction on the pharmaceutical industry. In addition, the longer the 
policy is applied, the more the pharmaceutical industry’s revenues will decrease. The 
decline in revenue to 16.8% occurred with the application of medicine pricing 
policies with direct price control methods, while the method of budget control and 
economic evaluation made about 6% lower revenue. The impact of reduction in 
revenues was not significant on the application of medicine pricing policies using 
profit controls and reference pricing (Sood et al., 2009). For example, over a 19-year 
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period (1986-2004) there was a decline in R&D spending in both countries that 
regulated medicine prices as in the EU and in countries that applied the free pricing 
system, such as the United States. However, the decline in R&D spending was 
greater in countries that implemented the regulation of medicine prices. In 1986, 
R&D spending in the EU was more than in the United States by 24%, while in 2004, 
R&D spending in the United States was 15% higher than in the EU countries (Golec 
and Vernon, 2006). In New Zealand, the application of reference pricing can affect 
the patient’s clinical outcomes. The determination of simvastatin as a medicine 
reference has failed to achieve success the outcome therapy.  In patients previously 
using fluvastatin who then switched to simvastatin, an increase in total cholesterol, 
LDL cholesterol and triglyceride levels occurred (Thomas et al., 1998). 
 
2.1.4 Indonesian Medicine Pricing Policy 
Setting medicine prices is also applied in Indonesia by the MoH. Each medicine 
price regulation is set forth in a decree. Since 2005–2011, the government has issued 
policies to regulate the prices of unbranded generic medicines. However, evidence 
that describes the method used to control medicine prices in Indonesia has not yet 
been demonstrated. Information is usually obtained from interpersonal 
communication or newspapers. In addition, there are no price regulations for branded 
generics, innovator brands (IBs) and patented medicines. The prices for all three 
types of medicines are determined by market mechanisms. The publication of 
medicine pricing policy studies in Indonesia remains very limited. 
 
 
 
